144-Week Data from Gilead Sciences, Inc.'s Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney

SYDNEY, Australia--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced the presentation of 144-week data from an ongoing clinical trial, Study 934, comparing a once-daily regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Sustiva® (efavirenz) to a twice-daily regimen of Combivir® (lamivudine/zidovudine) with Sustiva once daily in treatment-naïve adults with HIV. Data were presented by José Arribas, MD, of the University Hospital La Paz, Madrid, Spain at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention taking place July 22-25 in Sydney, Australia (Poster #WEPEB029).